NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 9 hours 26 min ago

NIDCR Dental Specialty and PhD Program (DSPP)(K12-Clinical Trials Not Allowed)

Mon, 12/11/2017 - 02:49
Funding Opportunity RFA-DE-18-012 from the NIH Guide for Grants and Contracts. The Dental Specialty and PhD Program (DSPP) FOA encourages applications for institutional research career development (K12) programs from organizations that propose to develop outstanding clinician scientists through an integrated program of advanced clinical training in a recognized dental specialty and supervised research training leading to a PhD in biomedical or behavioral science, or in another field applicable to dental, oral and craniofacial research. The program should accelerate the process of early career dentist scientists in achieving competencies in both clinical and research areas and facilitate the transition to an independent and productive research career dedicated to improving dental, oral and craniofacial health.
Categories: NIH-Funding

Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)

Mon, 12/11/2017 - 02:37
Funding Opportunity RFA-DK-17-035 from the NIH Guide for Grants and Contracts. NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing. Eventually, collections of iPSCs that capture the heterogeneity of T2D could be used to conduct "clinical trials in a dish", to discover biomarkers of response and to develop personalized treatments. An essential feature of this program will be a multidisciplinary approach that brings together basic science experts and physician scientists in stem cell biology, bioengineering, computational biology, pharmacology, liver biology, islet biology, adipose biology, metabolism and diabetes.
Categories: NIH-Funding

Academic Research Enhancement Award in Diseases within the Mission of NIDDK (R15 - Clinical Trial Required)

Mon, 12/11/2017 - 02:14
Funding Opportunity PA-18-495 from the NIH Guide for Grants and Contracts. The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution. The purpose of this FOA is to support AREA grants for clinical trials focused on diseases within the mission of NIDDK.
Categories: NIH-Funding

Notice of NICHD Participation in PAR-18-205 "NIBIB Biomedical Technology Resource Centers (P41 - Clinical Trial Optional)"

Fri, 12/08/2017 - 13:59
Notice NOT-HD-17-030 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of NIA Participation in PAR-16-355 "Social Epigenomics Research Focused on Minority Health and Health Disparities (R01)"

Fri, 12/08/2017 - 13:51
Notice NOT-AG-17-025 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of NIA Participation in PAR-16-356 "Social Epigenomics Research Focused on Minority Health and Health Disparities (R21)"

Fri, 12/08/2017 - 11:18
Notice NOT-AG-17-026 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R01 - Clinical Trial Optional)

Fri, 12/08/2017 - 03:49
Funding Opportunity RFA-HD-19-013 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity Announcement (FOA) is to encourage research into the role of pluripotent progenitor/stem cells in the pathogenesis and treatment of selected gynecologic disorders, specifically uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse.
Categories: NIH-Funding

Promoting Research in Basic Neuroscience (R01)

Fri, 12/08/2017 - 03:22
Funding Opportunity PAS-18-483 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related.
Categories: NIH-Funding

Notice of Expiration of PAR-15-289 "The Pancreatic Cancer Detection Consortium (U01)"

Fri, 12/08/2017 - 02:39
Notice NOT-CA-18-029 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of NINDS' Participation in PA-18-NNN "NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed)"

Fri, 12/08/2017 - 02:24
Notice NOT-NS-18-026 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of NIAMS' Participation in PA-18-369 "Mentored Research Scientist Development Award (Parent K01 -Independent Clinical Trial Not Allowed)

Fri, 12/08/2017 - 02:17
Notice NOT-AR-18-009 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trials Not Allowed)

Thu, 12/07/2017 - 13:56
Funding Opportunity RFA-EY-17-003 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders. This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement therapy. Model systems using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA. An important aspect of this FOA is that the research team is expected to treat the loss of vision associated with the experimental model using an approach that involves regenerating PRCs and/or RGCs and their connections. The choice of cells for therapy might include adult stem cells, precursors, stem cell derived progenitor cells, or conversion of intrinsic cells such as glia. It is expected that quantitative measures will be used to evaluate survival and integration of the regenerated cells using electrophysiology, functional imaging, behavioral measures or any other appropriate technology that would demonstrate circuit integration and restoration of visual function.
Categories: NIH-Funding